Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration |
| |
| Affiliation: | 1. The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel;2. Pfizer Pharma GmbH, Linkstrasse 10, 10785 Berlin, Germany;3. inVentiv Health Clinical, 504 Carnegie Center, Princeton, NJ 08540, USA;4. Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA;5. The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel;1. Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States;2. Expanded Programme on Immunization, Cook Islands Ministry of Health, P.O. Box 109, Rarotonga, Cook Islands;3. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States;4. Expanded Programme on Immunization, Kiribati Ministry of Health & Medical Services, P.O. Box 268, Nawerewere, Tarawa, Kiribati;5. Maternal and Child Health, World Health Organization Kiribati Country Office, Bikenibeu, Tarawa, Kiribati;6. Integrated Reproductive Health Coordinator, Tokelau Health Department Head Office, Nukunonu, Tokelau;7. Expanded Programme on Immunization, Niue Department of Health, P.O. Box 33, Alofi, Niue;1. Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50010, USA;2. College of Veterinary Medicine, Chonbuk National University, Iksan, Republic of Korea;3. Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50010, USA;4. Viral Disease Division, Animal Plant Fisheries Quarantine Agency, Anyang, Republic of Korea;3. Departamento de Bioquímica y Biología Molecular, Universidad de Córdoba; Campus de Excelencia Internacional CeiA3; and Red Española de Investigación en Patología Infecciosa (REIPI), Instituto de Salud Carlos III, Madrid, Spain;;4. Departamento de Sanidad Animal, Universidad de Córdoba; Campus de Excelencia Internacional CeiA3, Córdoba, Spain;;5. Sección de Enfermedades Infecciosas Pediátricas e Inmunopatología, Hospital Universitario Infantil Virgen del Rocío, Sevilla, Spain;1. Pfizer Deutschland GmbH, 10785 Berlin, Germany;2. Pfizer France, Paris, France;3. Pfizer Brazil, São Paulo, Brazil;4. Pfizer Vaccines, Collegeville, PA, USA |
| |
| Abstract: | BackgroundA prior 7- and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13) study provided sufficient data (N = 1754; Jewish, n = 1154; Bedouin, n = 595; other, n = 5) to investigate the association between nasopharyngeal (NP) acquisition of common PCV7 serotypes and cross-reacting 6A (PCV7 + 6A) and IgG concentrations.MethodsUsing a logistic regression model, serotype specific association between postinfant series IgG concentration (age 7 months) and new NP acquisition between ages 7 and 24 months was assessed and adjusted for ethnicity. From a subset of subjects with new NP acquisition (n = 9–152 across serotypes studied), new acquisition percentiles and associated IgG concentrations were calculated.ResultsFor the serotypes studied, new NP acquisition rates decreased as IgG concentrations increased. Ethnicity did not influence these associations despite differences in carriage rates. From the subset with new acquisitions, 50% of the events occurred at IgG concentrations >0.61–5.58 μg/mL; and 10% of the acquisitions occurred at IgG concentrations >2.48–17.69 μg/mL.ConclusionRemarkably high IgG concentrations are required to reduce NP acquisition. These IgG concentrations differ between serotypes. Ethnicity did not influence the association between high IgG concentrations and prevention of carriage despite differences in carriage rates. Since carriage determines transmission, these results may have important implications for herd protection.Trial registration: ClinicalTrials.gov number, NCT00508742; http://clinicaltrials.gov/ct2/show/NCT00508742 |
| |
| Keywords: | Pneumococcal conjugate vaccine Nasopharyngeal colonization Antibody concentrations Indirect protection Modeling |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
